ZA896464B - Use of 2-azabicyclo(2.2.2)octane-3-carboxylic acid derivatives for the production of medicinal products intended for the treatment of diseases resulting from impairment of the vascular wall as well as for disorders of the microcirculation - Google Patents

Use of 2-azabicyclo(2.2.2)octane-3-carboxylic acid derivatives for the production of medicinal products intended for the treatment of diseases resulting from impairment of the vascular wall as well as for disorders of the microcirculation

Info

Publication number
ZA896464B
ZA896464B ZA896464A ZA896464A ZA896464B ZA 896464 B ZA896464 B ZA 896464B ZA 896464 A ZA896464 A ZA 896464A ZA 896464 A ZA896464 A ZA 896464A ZA 896464 B ZA896464 B ZA 896464B
Authority
ZA
South Africa
Prior art keywords
microcirculation
azabicyclo
impairment
octane
disorders
Prior art date
Application number
ZA896464A
Other languages
English (en)
Inventor
Bernard Teisseire
Teisseire Bernard
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of ZA896464B publication Critical patent/ZA896464B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA896464A 1988-08-24 1989-08-24 Use of 2-azabicyclo(2.2.2)octane-3-carboxylic acid derivatives for the production of medicinal products intended for the treatment of diseases resulting from impairment of the vascular wall as well as for disorders of the microcirculation ZA896464B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8811157A FR2635684A1 (fr) 1988-08-24 1988-08-24 Utilisation de derives de l'acide aza - 2 bicyclooctane (2.2.2) carboxylique - 3 pour l'obtention de medicaments destines au traitement des maladies consecutives a l'alteration de la paroi vasculaire ainsi qu'aux troubles de la microcirculation

Publications (1)

Publication Number Publication Date
ZA896464B true ZA896464B (en) 1990-05-30

Family

ID=9369485

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA896464A ZA896464B (en) 1988-08-24 1989-08-24 Use of 2-azabicyclo(2.2.2)octane-3-carboxylic acid derivatives for the production of medicinal products intended for the treatment of diseases resulting from impairment of the vascular wall as well as for disorders of the microcirculation

Country Status (10)

Country Link
US (3) US5021425A (de)
EP (1) EP0360642A3 (de)
JP (1) JPH02108623A (de)
AU (1) AU620132B2 (de)
DK (1) DK417889A (de)
FR (1) FR2635684A1 (de)
NZ (1) NZ230413A (de)
OA (1) OA09130A (de)
PT (1) PT91515A (de)
ZA (1) ZA896464B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2002076981A1 (ja) * 2001-03-26 2004-10-07 壽製薬株式会社 イソキヌクリジン誘導体及びその製造方法並びにこれを含有する医薬組成物
EP3922403A1 (de) 2020-06-09 2021-12-15 Franz Kessler GmbH Werkzeugmaschineneinheit mit einem werkzeugsensor und verfahren zur erfassung einer schneidenbelastung eines werkzeuges

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492381A1 (fr) * 1980-10-21 1982-04-23 Science Union & Cie Nouveaux acides aza bicyclo alcane carboxyliques substitues leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
DE3227055A1 (de) * 1982-07-20 1984-01-26 Hoechst Ag, 6230 Frankfurt Neue derivate der 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure als zwischenstufe und verfahren zu deren herstellung

Also Published As

Publication number Publication date
DK417889D0 (da) 1989-08-24
PT91515A (pt) 1990-03-08
EP0360642A2 (de) 1990-03-28
EP0360642A3 (de) 1990-12-27
OA09130A (fr) 1991-10-31
JPH02108623A (ja) 1990-04-20
AU620132B2 (en) 1992-02-13
US5036076A (en) 1991-07-30
US5021425A (en) 1991-06-04
US5084452A (en) 1992-01-28
NZ230413A (en) 1991-04-26
DK417889A (da) 1990-02-25
AU4016189A (en) 1990-03-01
FR2635684A1 (fr) 1990-03-02

Similar Documents

Publication Publication Date Title
GB2247837B (en) Pharmaceutical product for the treatment of immunoregulatory disorders
HU912266D0 (en) Process for the production of solid medical preparations with controlled portioning of the active agents for oral use
GR890100797A (en) Process for manufacturing pharmaceutical compositions comprising acetyl d-carnitine for the therapeutic treatment of glaucoma
NO883974D0 (no) Fremgangsmaate for fremstilling av terapeutiske aktive tetrahydro-hydroksypyranon-derivater.
NO880182D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1, 2-dihydro-3h-indazol-3h-indazol-3-on-derivater.
HU208256B (en) Process for producing pharmaceutical compositions suitable for the selective reduction of lipoid level of blood
IL86423A0 (en) Pharmaceutical compositions for the treatment of alzheimer's disease
PT84899A (en) Process for the preparation of pharmaceutical compositions containing ?-phenyl-1,2-benzisoselenazol-3(2h)-one for the treatment of skin diseases
NO893270L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydropyridineddiksyrederivater.
IT8322855A0 (it) Composizione farmaceutica per la cura delle arteriopatie periferiche.
IL90551A (en) Stable, injectable, aqueous pharmaceutical compositions for the treatment of cardiac conditions
NO171412C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-oksatiolan- eller 1,3-ditiolanderivater
NO883122L (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylamid-derivater.
AR245125A1 (es) Procedimiento para la preparacion de compuestos arilpiperazinil-alquilenfenil-p-heterociclicos y sus sales de adicion de acidos farmaceuticamente aceptables.
NO874850D0 (no) Fremgangsmaate for fremstilling av benzotiadiazinforbindelser og farmasoeytisk akseptable salter derav.
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
ATE137237T1 (de) R-(-)-1-(5-hydroxyhexyl)-3-methyl-7- propylxanthin, verfahren zu dessen herstellung und diese verbindung enthaltende arzneimittel
ZA875847B (en) Pharmaceutical compositions for the treatment of occlusive vascular diseases
GB2204488B (en) Pharmaceutical compositions for the treatment or prophylaxis of skin disorders
ZA896464B (en) Use of 2-azabicyclo(2.2.2)octane-3-carboxylic acid derivatives for the production of medicinal products intended for the treatment of diseases resulting from impairment of the vascular wall as well as for disorders of the microcirculation
TR27058A (tr) 2-azabisiklo (2,2,1) hept-5-ene-2 asetik asid bunun türevleri ve ilgili bilesimleri mezkur bilesimlerin hazirlanmasi usul ve mezkur bilesimlerin n-fosfonometilglisin imali icin kullanilmasi.
NO172491C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksan-alkensyre-dervater
EP0269452A3 (de) Anwendung von Keton-Derivaten zur Herstellung von Arzneimitteln
HUT53288A (en) Process for production of medical compositions for animals against endoparasite
AP9000180A0 (en) Pharmaceutical composition for the treatment of protozoal diseases